Epigenic Therapeutics is a frontier biotechnology company dedicated to developing next generation gene editing therapy utilizing regulation of epigenetic genome for a variety of diseases. Founded in 2021 by leading scientists focused on discovering gene editing technologies and developing gene editing therapies, the company has multiple product candidates in the pipeline, including treatment for metabolic, cardiovascular, viral hepatitis, ocular and rare diseases.
Company Details
- Employees
- 14
- Founded
- -
- Address
- 上海浦东新区上海自贸壹号生命科技产业园(一期)4-15f6f, 上海,上海,china
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.epigenictx.com
- Keywords
- gene therapy and epigenetic editing.
- HQ
- 上海, 上海
Epigenic Therapeutics Questions
Epigenic Therapeutics's website is http://www.epigenictx.com
Epigenic Therapeutics's LinkedIn profile is https://cn.linkedin.com/company/epigenic-therapeutics
Epigenic Therapeutics has
14 employees.
View email and phone details for 14
employees at Epigenic Therapeutics.
Epigenic Therapeutics's industry is
Biotechnology Research
Epigenic Therapeutics's top competitors are
Neochimed,
Innovative Cellular Therapeutics (Ict),
Qiming Venture Partners,
Recibiopharm,
Tandemai,
Kunming Biomed International (Kbi),
Hd Biosciences Co., Ltd,
Immunocan,
Sorrento Therapeutics, Inc.,
Enqubio Inc..
Epigenic Therapeutics's categories are Biotechnology Research
Epigenic Therapeutics's founding year is 2021
